| Description | AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator and it has an IC50 of 1.2 nM for CCR2 Ca2+ flux [1][2][3]. |
| In vitro | AZD2423 inhibits MCP-1 induced calcium mobilization and chemotaxis of THP-1 cell line with an IC50 of 4 nM[1]. |
| molecular weight | 425.93 |
| Molecular formula | C20H29ClFN5O2 |
| CAS | 1229603-37-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. AZD2423. 2. John G. Cumming. CCR2 antagonists for the treatment of neuropathic pain: The discovery and development of AZD2423. 3. Kalliomäki J, et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013 May;154(5):761-7. |